News Sentiment

APGE sentiment intelligence

Apogee Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 75 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 134.00 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 67

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+0.3% over one week, +48.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Apogee Therapeutics stock hits all-time high at 134.34 USD

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend active 48.3% over four weeks
Fair value 168.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 52
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 67
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 11
TradingView 7
Investing.com 4
Motley Fool 3
timothysykes.com 3
Investing.com Nigeria 2
StocksToTrade 2

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 19
Deals and strategy 8
Capital return 1
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 75
Finviz Direct company coverage

APGE - Apogee Therapeutics Inc Revenue Breakdown

This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss

Tone
Positive 60/100
Event
Earnings
Published
03 Jul 2026 22:10
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Apogee Therapeutics, Inc. – NASDAQ:APGE

This article focuses on the "Price to sales forward" metric for Apogee Therapeutics, Inc. (NASDAQ: APGE). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical data, and forecasts. The page structure also

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:39
Source
TradingView
Stock Titan Direct company coverage

Apogee Therapeutics (APGE) CMO sells shares, exercises options under 10b5-1 plan

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported an option exercise and a related sale of company shares. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved exercising options for 4,125 shares at $22.86 each and selling 5,500 s

Tone
Negative 38/100
Event
Market update
Published
03 Jul 2026 00:39
Source
Stock Titan
Investing.com Direct company coverage

Apogee Therapeutics stock hits all-time high at 133.32 USD

Apogee Therapeutics' stock has reached an all-time high of $133.32, with a soaring 1-year return of nearly 200%, reflecting significant investor confidence. This surge comes amid news of an acquisition by AbbVie for $135.11 per share and ongoing strategic developments like antibo

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 22:10
Source
Investing.com
ETF Database Direct company coverage

Biotech Gives SBIO Its Best Month Since 2023

The ALPS Medical Breakthroughs ETF (SBIO) experienced its best single month since December 2023, returning 18.7% in June, primarily driven by biotech stock performance. Key contributors included Apogee, Definium, and Oruka, with significant surges due to drug trial results and a

Tone
Positive 86/100
Event
Earnings
Published
02 Jul 2026 17:39
Source
ETF Database
24/7 Wall St. Direct company coverage

Apogee Therapeutics : APGE

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 07:00
Source
24/7 Wall St.